Novartis CEO said that they are currently researching a price reduction plan for the US market in order to maintain revenue growth expectations.

Novartis CEO Vas Narasimhan said in an interview on Saturday that the company is studying a plan to lower drug prices for President Trump before the end of this month. Narasimhan said, "We are working with the government to find practical solutions so that Americans can buy drugs at lower prices." He added that the company is also working to eliminate the price gap between drugs in the United States and other industrialized countries. Narasimhan said that Novartis has not adjusted its expectations due to Trump's demands and still expects mid-term revenue to grow by 5% from 2024 to 2029, with profit growth expected to exceed revenue growth. Narasimhan also said that Novartis is prepared for the 15% tariff on European Union drugs imposed by the United States, "We have significantly increased our inventory in the United States, so this inventory will definitely last until the mid-2026."